Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
- Associated Therapies
- -
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Yang Li
- Target Recruit Count
- 65
- Registration Number
- NCT03503864
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
- Conditions
- Interventions
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Li Junmin
- Target Recruit Count
- 100
- Registration Number
- NCT03381781
- Locations
- 🇨🇳
Shanghai Institute of Hematology, Shanghai, China
🇨🇳Ruijin Hospital North, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai, China
Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Li Junmin
- Registration Number
- NCT03377725
- Locations
- 🇨🇳
Ruijin Hospital North, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai, China
🇨🇳Shanghai Institute of Hematology, Shanghai, China
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2020-03-20
- Target Recruit Count
- 80
- Registration Number
- NCT03031249
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Hunan Provincial People's Hospital
- Target Recruit Count
- 190
- Registration Number
- NCT02956772
- Locations
- 🇨🇳
The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
🇨🇳Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳Guizhou Province Tumor Hospital, Guiyang, Guizhou, China
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2021-09-08
- Target Recruit Count
- 110
- Registration Number
- NCT02899169
- Locations
- 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Jean Yuh Tang
- Registration Number
- NCT02699723
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 280
- Registration Number
- NCT02688140
- Locations
- 🇩🇪
OSHO study group, Multiple Locations, Germany
🇩🇪SAL study group, Multiple Locations, Germany
🇳🇱HOVON study group, Multiple Locations, Netherlands
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 158
- Registration Number
- NCT02339740
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸Naval Medical Center -San Diego, San Diego, California, United States
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
- Conditions
- Interventions
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 92
- Registration Number
- NCT02190695
- Locations
- 🇺🇸
Temple BMT Program at Jeanes Hospital, Philadelphia, Pennsylvania, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.